Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock
Net proceeds to fund the Company’s strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases CANTON, Mass. (November 12, 2024) – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine […]